Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We describe the small-scale, laboratory-based, production and quality control of a cocktail, consisting of exclusively lytic bacteriophages, designed for the treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections in burn wound patients. Based on successive selection rounds three bacteriophages were retained from an initial pool of 82 P. aeruginosa and 8 S. aureus bacteriophages, specific for prevalent P. aeruginosa and S. aureus strains in the Burn Centre of the Queen Astrid Military Hospital in Brussels, Belgium. This cocktail, consisting of P. aeruginosa phages 14/1 (Myoviridae) and PNM (Podoviridae) and S. aureus phage ISP (Myoviridae) was produced and purified of endotoxin. Quality control included Stability (shelf life), determination of pyrogenicity, sterility and cytotoxicity, confirmation of the absence of temperate bacteriophages and transmission electron microscopy-based confirmation of the presence of the expected virion morphologic particles as well as of their specific interaction with the target bacteria. Bacteriophage genome and proteome analysis confirmed the lytic nature of the bacteriophages, the absence of toxin-coding genes and showed that the selected phages 14/1, PNM and ISP are close relatives of respectively F8, phiKMV and phage G1. The bacteriophage cocktail is currently being evaluated in a pilot clinical study cleared by a leading Medical Ethical Committee.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.403-434.2006 · Cited by 1,876
Influence of pH on wound-healing: a new perspective for wound-therapy?
Schneider, L. A., Korber, A., Grabbe, S., & Dissemond, J. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-006-0713-x · Cited by 1,066
Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy
Bruttin, A., & Brüssow, H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2874-2878.2005 · Cited by 563
Smith, H. W., & Huggins, M. B. (1982) · Microbiology · doi:10.1099/00221287-128-2-307 · Cited by 518
Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., Carlton, R., & Merril, C. R. (2002) · Infection and Immunity · doi:10.1128/iai.70.1.204-210.2002 · Cited by 467
Smith, H. W., & Huggins, M. B. (1983) · Microbiology · doi:10.1099/00221287-129-8-2659 · Cited by 436
The prospect for bacteriophage therapy in Western medicine
Merril, C. R., Scholl, D., & Adhya, S. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1111 · Cited by 367
The Control of Experimental Escherichia coli Diarrhoea in Calves by Means of Bacteriophages
Smith, H. W., Huggins, M. B., & Shaw, K. M. (1987) · Microbiology · doi:10.1099/00221287-133-5-1111 · Cited by 365
Techniques in Microbial Ecology
(1990) · Methods in Microbiology · doi:10.1016/s0580-9517(08)x7011-4 · Cited by 320
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Syndemics and the biosocial conception of health
Singer, M., Bulled, N., Ostrach, B., & Mendenhall, E. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30003-x · Cited by 1,491
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Self-citationWittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
Applying insights from biofilm biology to drug development — can a new approach be developed?
Bjarnsholt, T., Ciofu, O., Molin, S., Givskov, M., & Høiby, N. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4000 · Cited by 516
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
Pirnay, J.-P., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., Glonti, T., Spiessens, A., Vanden Berghe, E., Green, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01705-x · Cited by 474
Self-citationPhage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Phage Therapy—History from Twort and d'Herelle Through Soviet Experience to Current Approaches
Chanishvili, N. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00001-3 · Cited by 407
Self-citationPhage on tap–a quick and efficient protocol for the preparation of bacteriophage laboratory stocks
Bonilla, N., Rojas, M. I., Netto Flores Cruz, G., Hung, S.-H., Rohwer, F., & Barr, J. J. (2016) · PeerJ · doi:10.7717/peerj.2261 · Cited by 353
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Treatment, promotion, commotion: antibiotic alternatives in food-producing animals
Allen, H. K., Levine, U. Y., Looft, T., Bandrick, M., & Casey, T. A. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2012.11.001 · Cited by 320
The next generation of bacteriophage therapy
Lu, T. K., & Koeris, M. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.028 · Cited by 312
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0313-5 · Cited by 298
Self-citationMcCallin, S., Alam Sarker, S., Barretto, C., Sultana, S., Berger, B., Huq, S., Krause, L., Bibiloni, R., Schmitt, B., Reuteler, G., et al. (2013) · Virology · doi:10.1016/j.virol.2013.05.022 · Cited by 265
Alternatives to overcoming bacterial resistances: State-of-the-art
Rios, A. C., Moutinho, C. G., Pinto, F. C., Del Fiol, F. S., Jozala, A., Chaud, M. V., Vila, M. M. D. C., Teixeira, J. A., & Balcão, V. M. (2016) · Microbiological Research · doi:10.1016/j.micres.2016.04.008 · Cited by 263
Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A.-S., & Lavigne, R. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312804871193 · Cited by 261
Self-citationBacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Bacteriophage–host interaction: from splendid isolation into a messy reality
Brüssow, H. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.04.007 · Cited by 49
“coli and T phages, but they are reasonably well characterized for such an approach [51 ,52].”
Background
Metadata
- Authors
- Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., Lavigne, R., Volckaert, G., Mattheus, W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D., & Vaneechoutte, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-20
- Volume
- 4
- Issue
- 3
- Pages
- e4944
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2070373460
- Cited by
- 511
- References
- 25
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.